Text Size : A | A | A

Publications

Bacterial Respiratory Tract Infections

Access peer-reviewed literature about the treatment of bacterial respiratory tract infections:

A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. File TM Jr, Segreti J, Dunbar L, et al. Antimicrob Agents Chemother. 1997;41(9):1965-1972.

Antimicrobial resistance trends among sinus isolates of Streptococcus pneumoniae in the United States (2001-2005). Sahm DF, Benninger MS, Evangelista AT, Yee YC, Thornsberry C, Brown NP. Otolaryngol Head Neck Surg. 2007;136:385-389.

Clinical implications of 750 mg, 5-day levofloxacin for the treatment of community-acquired pneumonia. File TM Jr, Milkovich G, Tennenberg AM, Xiang JX, Khashab MM, Zadeikis N. Curr Med Res Opin. 2004;20(9): 1473-1481.

Levofloxacin versus azithromycin on the oropharyngeal carriage and selection of antibacterial-resistant streptococci in the microflora of healthy adults. Nord CE, Peterson J, Ambruzs M, Fisher AC. Curr Med Res Opin. 2009;25(6):1461-1467.

Pharmacodynamics of 750 mg and 500 mg doses of levofloxacin against ciprofloxacin-resistant strains of Streptococcus pneumoniae. Lister PD. Diagn Microbiol Infect Dis. 2002;44:43-49.

Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Mandell LA, Wunderink RG, Anzueto A, et al. Clin Infect Dis. 2007;44:S27-S72.

Back to top

Genitourinary Infections

Familiarize yourself with the studies and articles dealing with the treatment of GUIs:

Levofloxacin versus ciprofloxacin in the treatment of chronic bacterial prostatitis: a randomized double-blind multicenter study. Bundrick W, Heron SP, Ray P, et al. Urology. 2003;62:537-541.

Oral levofloxacin 500 mg once daily in the treatment of chronic bacterial prostatitis.Naber KG, Roscher K, Botto H, Schaefer V. Int J Antimicrob Agents. 2008;32:145-153.

Back to top

Hospital Infections

Keep current on what other physicians and researchers are saying about the treatment of bacterial infections in the hospital environment with these informative articles:

A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. Loo VG, Poirier L, Miller MA, et al. N Engl J Med. 2005;353:2442-2449.

Levofloxacin compared with imipenem/cilastatin followed by ciprofloxacin in adult patients with nosocomial pneumonia: a multicenter, prospective, randomized, open-label study. West M, Boulanger BR, Fogarty C, et al. Clin Ther. 2003;25(2):485-506.

Drug costs and bacterial susceptibility after implementing a single-fluoroquinolone use policy at a university hospital. Rapp RP, Evans ME, Martin C, Ofotokum I, Empey KL, Armitstead JA. Curr Med Res Opin. 2004;20(4):469-476.

Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Dellit TH, Owens RC, McGowan JE Jr, et al. Clin Infect Dis. 2007;44:159-177.

Public reporting and pay for performance in hospital quality improvement. Lindenauer PK, Remus D, Roman S, et al. N Engl J Med. 2007;356:486-496.

A controlled trial of a critical pathway for treatment of community-acquired pneumonia. Marrie TJ, Lau CY, Wheeler SL, Wong CJ, Vandervoort MK, Feagan BG. JAMA. 2000;283(6):749-755.

Medical resource utilization among community-acquired pneumonia patients initially treated with levofloxacin 750 mg daily versus ceftriaxone 1000 mg plus azithromycin 500 mg daily: a US-based study. Frei CR, Jaso TC, Mortensen EM, et al. Curr Med Res Opin. 2009;25(4):859-868.

A comparison of levofloxacin and moxifloxacin use in hospitalized community-acquired pneumonia (CAP) patients in the US: focus on length of stay. Schein J, Janagap-Benson C, Grant R, Sikirica V, Doshi D, Olson W. Curr Med Res Opin. 2008;24(3):895-906.

Back to top